Viking Therapeutics (VKTX) Consolidated Net Income: 2014-2025
Historic Consolidated Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.8 million.
- Viking Therapeutics' Consolidated Net Income fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Consolidated Net Income is -$90.8 million, which was down 38.52% from -$65.5 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Consolidated Net Income registered a high of -$12.4 million during Q4 2021, and its lowest value of -$90.8 million during Q3 2025.
- In the last 3 years, Viking Therapeutics' Consolidated Net Income had a median value of -$25.0 million in 2024 and averaged -$36.2 million.
- Data for Viking Therapeutics' Consolidated Net Income shows a maximum YoY tumbled of 262.79% (in 2025) over the last 5 years.
- Over the past 5 years, Viking Therapeutics' Consolidated Net Income (Quarterly) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then decreased by 25.72% to -$24.6 million in 2023, then crashed by 44.00% to -$35.4 million in 2024, then slumped by 262.79% to -$90.8 million in 2025.
- Its Consolidated Net Income was -$90.8 million in Q3 2025, compared to -$65.5 million in Q2 2025 and -$45.6 million in Q1 2025.